UniQure NV shares soared after the company announced it will be able to seek US approval for its Huntington’s disease gene therapy before conducting a new study, a dramatic reversal that shows the ...
Investor's Business Daily on MSN
UniQure catapults nearly 80% on a gene therapy shock from the FDA
UniQure stock catapulted Wednesday after announcing the FDA would allow it to refile its Huntington's disease gene therapy.
18d
UniQure to seek FDA approval for Huntington's disease gene therapy after previous clash with agency
The announcement comes months after UniQure became embroiled in a public debate with FDA leaders over the clinical trial data ...
Learn more about whether uniQure N.V. or Viridian Therapeutics, Inc. is a better investment based on AAII's A+ Investor ...
The decision marks another regulatory U-turn following the exits of Marty Makary and Vinay Prasad, suggesting to some analysts that current FDA leadership may be more flexible in certain cases.
QURE looks stronger as the FDA reopens the AMT-130 BLA path for Huntington’s gene therapy. Click here to read more about the ...
Moderna (MRNA) stock and Capricor Therapeutics (CAPR) stock are in focus as the firms look to benefit from policy reversals ...
Leerink Partners and Stifel are acting as bookrunning managers for the proposed offering.
A first-of-its-kind drug may slow the progression of Huntington's disease, a rare, fatal, neurodegenerative disorder.
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
LEXINGTON, Mass. and AMSTERDAM, June 25, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing ...
Shares of uniQure N.V. (NASDAQ: QURE) are crashing today, down by 32.6% as of 11:19 a.m. ET. The steep decline came after the gene therapy specialist provided its second-quarter update Monday morning.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results